210 related articles for article (PubMed ID: 35607768)
1. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.
Ma Y; Wang Y; Dong C; Gonzalez GX; Zhu W; Kim J; Wei L; Kang SM; Wang BZ
Small; 2022 Jun; 18(25):e2200836. PubMed ID: 35607768
[TBL] [Abstract][Full Text] [Related]
2. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2.
Grant MD; Bentley K; Fielding CA; Hatfield KM; Ings DP; Harnum D; Wang EC; Stanton RJ; Holder KA
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37338994
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.
Balinsky CA; Jiang L; Jani V; Cheng Y; Zhang Z; Belinskaya T; Qiu Q; Long TK; Schilling MA; Jenkins SA; Corson KS; Martin NJ; Letizia AG; Hontz RD; Sun P
Front Immunol; 2023; 14():1266829. PubMed ID: 38077368
[TBL] [Abstract][Full Text] [Related]
4. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 spike S2-specific neutralizing antibodies.
Li CJ; Chang SC
Emerg Microbes Infect; 2023 Dec; 12(2):2220582. PubMed ID: 37254830
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
7. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
8. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
Shah P; Canziani GA; Carter EP; Chaiken I
Front Immunol; 2021; 12():637651. PubMed ID: 33767706
[TBL] [Abstract][Full Text] [Related]
9. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern.
Heo CK; Lim WH; Yang J; Son S; Kim SJ; Kim DJ; Poo H; Cho EW
Front Immunol; 2023; 14():1307693. PubMed ID: 38143750
[TBL] [Abstract][Full Text] [Related]
10. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
[TBL] [Abstract][Full Text] [Related]
11. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.
Ng KW; Faulkner N; Finsterbusch K; Wu M; Harvey R; Hussain S; Greco M; Liu Y; Kjaer S; Swanton C; Gandhi S; Beale R; Gamblin SJ; Cherepanov P; McCauley J; Daniels R; Howell M; Arase H; Wack A; Bauer DLV; Kassiotis G
Sci Transl Med; 2022 Jul; 14(655):eabn3715. PubMed ID: 35895836
[TBL] [Abstract][Full Text] [Related]
14. Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses.
Halfmann PJ; Frey SJ; Loeffler K; Kuroda M; Maemura T; Armbrust T; Yang JE; Hou YJ; Baric R; Wright ER; Kawaoka Y; Kane RS
EBioMedicine; 2022 Dec; 86():104341. PubMed ID: 36375316
[TBL] [Abstract][Full Text] [Related]
15. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.
Hsieh CL; Leist SR; Miller EH; Zhou L; Powers JM; Tse AL; Wang A; West A; Zweigart MR; Schisler JC; Jangra RK; Chandran K; Baric RS; McLellan JS
Nat Commun; 2024 Feb; 15(1):1553. PubMed ID: 38378768
[TBL] [Abstract][Full Text] [Related]
16. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
[TBL] [Abstract][Full Text] [Related]
17. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
19. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses.
Silva RP; Huang Y; Nguyen AW; Hsieh CL; Olaluwoye OS; Kaoud TS; Wilen RE; Qerqez AN; Park JG; Khalil AM; Azouz LR; Le KC; Bohanon AL; DiVenere AM; Liu Y; Lee AG; Amengor DA; Shoemaker SR; Costello SM; Padlan EA; Marqusee S; Martinez-Sobrido L; Dalby KN; D'Arcy S; McLellan JS; Maynard JA
Elife; 2023 Mar; 12():. PubMed ID: 36942851
[TBL] [Abstract][Full Text] [Related]
20. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein.
Hong Y; Guo H; Wei M; Zhang Y; Fang M; Cheng T; Li Z; Ge S; Yao X; Yuan Q; Xia N
J Virol Methods; 2022 Sep; 307():114564. PubMed ID: 35671888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
